



# PHILLIP RESEARCH SDN BHD

199001007125 (198695-X)

B-18-6, Megan Avenue II, No 12, Jalan Yap Kwan Seng, 50450 Kuala Lumpur.

Tel No: 03-2783 0300

## Capital Market Navigator

| 2<sup>nd</sup> August 2023 |

### | MALAYSIA COMPANY UPDATE |

#### LAGENDA PROPERTIES BERHAD (LAGENDA MK)

**RATING**

: BUY

**TARGET PRICE**

: MYR1.54

**CLOSING PRICE (2<sup>nd</sup> August 2023)**

: MYR1.18

#### Lagenda BBSAP Township Site Visit Update

- This township has a total span of 1.2k acres with an estimated gross development value (GDV) of MYR3 billion. Out of the total MYR3 billion GDV, MYR2.36 billion GDV have been launched in phases with an average take-up rate of 86% as at 31st March 2023.
- The recent inclusion of Lagenda in the FTSE4Good and F4GBMS indices with a 3-star ESG rating stands as a testament to the group's commitment and continuous efforts towards sustainable practices.
- We maintain our BUY rating with a Target Price of MYR1.54 pegged to mean forward PE of 5.36x for FY2023E, which translates to a 30.28% upside. We believe Lagenda's long-term growth prospects will remain attractive, supported by the ongoing expansion of the group to other states and the resilient demand for its affordable landed houses.

#### Price Chart



Source: Bloomberg

#### Price Fundamentals

Market Capitalization (MYR' bil)	0.98
52-Week High (MYR)	1.34
52-Week Low (MYR)	1.13

#### Major Shareholders

Lagenda Land Sdn. Bhd.	63.92%
Setia Awan Plantation Sdn. Bhd.	4.49%
Doh Properties Holdings Sdn. Bhd.	4.49%

Source: Bursamarketplace, Bloomberg as at 2<sup>nd</sup> August 2023


Financial Summary (MYR '000)	FY2020	FY2021	FY2022	FY2023E	FY2024E	FY2025E
Revenue	697,612	835,578	866,940	1,163,572	1,336,563	1,494,251
EBITDA	227,877	294,526	270,182	361,448	410,949	455,889
Net Profit	151,687	201,466	178,226	240,160	256,250	285,020
EPS (sen)	57.8	25.1	21.3	28.7	30.6	34.0
EPS Growth (%)	38.2%	-56.6%	-15.2%	34.7%	6.7%	11.2%
P/E (x)	2.0	4.7	5.5	4.1	3.9	3.5
DPS (sen)	2.5	6.5	6.5	7.2	7.6	8.5
Dividend Yield (%)	2.0%	5.2%	5.2%	5.8%	6.2%	6.9%
BPS (sen)	238.8	109.8	121.4	145.8	174.3	212.3
P/B (x)	0.5	1.1	1.0	0.8	0.7	0.6
ROE (%)	30.1%	26.7%	18.8%	21.5%	19.1%	17.6%
Net Gearing (x)	0.06	Net Cash	Net Cash	Net Cash	0.3	0.3

Source: Company, PRSB

**Opinion/Outlook**

**Legenda’s model.** The main mission of Legenda has always been to provide affordable housing solutions for the underserved market. To achieve that, the group will do a thorough study on the maximum affordability of the B40 group in each respective area so that Legenda can sell its housing at a price range that is truly affordable to this income group. This strategy was visible in the group’s penetration into the Perak Housing market with its first affordable township Bandar Baru Setia Awan Perdana (BBSAP) as shown in Exhibit 1. The key to maintain its profitability by only selling affordable housing lies in its ability to source for large parcels of land in second tier cities that have lower land costs (approximately. 10-20% of GDV). By capitalising on this advantage, the group can efficiently develop thousands of units with consistent designs and layouts, enabling economies of scale across developments. This strategic approach optimises costs and enhances the affordability of homes, contributing to the company’s continued success.

Exhibit 1: Housing Market in Perak



Source: Company


**BBSAP township visit.** Bandar Baru Setia Awan Perdana (BBSAP) is Legenda’s first affordable township development that commenced back in 2016, which was before Legenda assumed its listing status in 2020. This township has a total span of 1.2k acres with an estimated gross development value (GDV) of MYR3 billion. Out of the total MYR3 billion GDV, MYR2.36 billion GDV have been launched in phases with an average take-up rate of 86% as at 31<sup>st</sup> March 2023. The selling price of this township ranges from MYR135k – MYR250k. During our analysts’ site visit to the township, it became evident that the development is thoughtfully planned and equipped with essential infrastructure. Furthermore, ample land has been designated for key facilities such as schools, medical centre, and commercial areas.

Moreover, the management’s commitment to enhancing residents’ living experience extends beyond the basics. Residents can enjoy the recreational facilities conveniently housed within the township’s Clubhouse. From an Olympic-sized swimming pool to a fully equipped gym, badminton courts as well and a playground, every amenity is designed to add significant value and delight to the community’s lifestyle. The management also shared that they are always engaging with the residents to understand more about how they would like to improve the facilities provided in the hope of creating a sustainable township that addresses the needs of the residents.

**ESG recognitions.** The recent inclusion of Legenda in the FTSE4Good and F4GBMS indices with a 3-star ESG rating stands as a testament to the group’s commitment and continuous efforts towards sustainable practices.

**Expectations.** Lagenda is committed to launching 7,300 units of houses and 1,200 Kampung Tersusun lots, which total up to MYR1.5 billion GDV in FY2023 (Exhibit 2). As at 1QFY23, the group has launched 1,700 units with a GDV of MYR347 million. Unbilled sales stood at MYR782 million, which would largely (approximately 50%) be recognised by the end of the year as construction activities ramp up across various projects. While the remaining GDV stood at MYR12.73 billion to ensure a steady project pipeline in the next 5-8 years.

Exhibit 2: Planned launches



Source: Company

**Maintain forecasts.** We maintain our BUY rating with a Target Price of MYR1.54 pegged to mean forward PE of 5.36x for FY2023E, which translates to a 30.28% upside. We believe Lagenda’s long-term growth prospects will remain attractive, supported by the ongoing expansion of the group to other states and the resilient demand for its affordable landed houses.

Exhibit 3: PE Band



Source: Company, PRSB

Income Statement (MYR,000)	2020	2021	2022	2023E	2024E	2025E
<b>Revenue</b>	<b>697,612</b>	<b>835,578</b>	<b>868,080</b>	<b>1,163,572</b>	<b>1,336,563</b>	<b>1,494,251</b>
COGS	-420,630	-511,497	-549,071	-734,214	-855,400	-948,850
<b>Gross profits</b>	<b>276,982</b>	<b>324,081</b>	<b>319,009</b>	<b>429,358</b>	<b>481,163</b>	<b>545,402</b>
SG&A	-57,880	-68,880	-79,864	-100,839	-117,477	-134,057
Other income	7,002	36,928	26,917	29,631	43,216	39,687
<b>Operating profits</b>	<b>226,105</b>	<b>292,129</b>	<b>266,062</b>	<b>358,151</b>	<b>406,902</b>	<b>451,032</b>
Share of results from associated companies and joint venture	-600	-	46	-	-	-
<b>Earnings before interest &amp; tax (EBIT)</b>	<b>225,504</b>	<b>292,129</b>	<b>266,108</b>	<b>358,151</b>	<b>406,902</b>	<b>451,032</b>
Finance cost	-9,562	-13,050	-15,298	-20,374	-46,494	-50,160
<b>Profit before tax</b>	<b>215,943</b>	<b>279,079</b>	<b>250,810</b>	<b>337,777</b>	<b>360,408</b>	<b>400,872</b>
Taxation	-64,256	-77,613	-73,074	-97,618	-104,158	-115,852
<b>Profit for the year</b>	<b>151,687</b>	<b>201,466</b>	<b>177,736</b>	<b>240,160</b>	<b>256,250</b>	<b>285,020</b>
Minority interests	9,200	-40	5,525	-45	-48	-52
<b>Net profits ex-MI</b>	<b>142,487</b>	<b>201,426</b>	<b>172,211</b>	<b>240,115</b>	<b>256,203</b>	<b>284,968</b>
<b>Net profits ex-MI &amp; extraordinary</b>	<b>142,487</b>	<b>201,426</b>	<b>172,211</b>	<b>240,115</b>	<b>256,203</b>	<b>284,968</b>
<b>% y-y</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023E</b>	<b>2024E</b>	<b>2025E</b>
Sales	50.7%	19.8%	3.9%	34.2%	14.9%	11.8%
COGS	49.6%	21.6%	7.3%	34.2%	16.5%	10.9%
Gross profits	52.6%	17.0%	-1.6%	34.3%	12.1%	13.4%
SG&A	72.1%	19.0%	15.9%	23.0%	16.5%	14.1%
Operating profits	50.5%	29.2%	-8.9%	34.3%	13.6%	10.8%
Earnings before interest & tax (EBIT)	50.1%	29.5%	-8.9%	34.2%	13.6%	10.8%
EBITDA	227,877	294,526	269,425	361,448	410,949	455,889
EBITDA Growth	50.1%	29.2%	-8.5%	33.8%	13.7%	10.9%
EBITDA Margin	32.7%	35.2%	31.0%	31.1%	30.7%	30.5%
Profit before tax	54.0%	29.2%	-10.1%	34.3%	6.7%	11.2%
Taxation and zakat	57.2%	20.8%	-5.8%	33.2%	6.7%	11.2%
Net profits ex-MI	48.3%	41.4%	-14.5%	34.7%	6.7%	11.2%
<b>As % of sales</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023E</b>	<b>2024E</b>	<b>2025E</b>
COGS	60.3%	61.2%	63.3%	63.1%	64.0%	63.5%
Gross profits	39.7%	38.8%	36.7%	36.9%	36.0%	36.5%
SG&A	8.3%	8.2%	9.2%	8.7%	8.8%	9.0%
Operating profits	32.4%	35.0%	30.6%	30.8%	30.4%	30.2%
Earnings before interest & tax (EBIT)	32.3%	35.0%	30.7%	30.8%	30.4%	30.2%
Profit before tax	31.0%	33.4%	28.9%	29.0%	27.0%	26.8%
Taxation	29.8%	27.8%	29.1%	28.9%	28.9%	28.9%
Net profits ex-MI	20.4%	24.1%	19.8%	20.6%	19.2%	19.1%
Depreciation & Amortisation	0.3%	0.3%	0.4%	0.3%	0.3%	0.3%
Capex	0.1%	5.3%	5.3%	3.2%	34.3%	4.3%
Depreciation & Amortisation	1,772	2,396	3,363	3,297	4,047	4,856
Capex	1,022	44,477	45,825	37,741	457,943	63,602
Shares out (FY-avg)	262,339	802,299	836,689	837,327	837,327	837,327
EPS (sen)	57.82	25.11	21.24	28.68	30.60	34.04
Core EPS (sen)	54.31	25.11	20.58	28.68	30.60	34.03
EPS Growth	38.2%	-56.6%	-15.4%	34.7%	6.7%	11.2%
DPS (sen)	2.50	6.50	6.50	7.17	7.65	8.51
Dividend payout	4.6%	25.9%	31.6%	25.0%	25.0%	25.0%
BPS (sen)	238.76	109.76	121.39	145.82	174.27	212.32

Source: Company, compiled by PRSB

Balance sheet (MYR,000)	2020	2021	2022	2023E	2024E	2025E
<b>Current assets</b>	<b>988,828</b>	<b>1,248,586</b>	<b>1,524,571</b>	<b>1,773,645</b>	<b>1,853,482</b>	<b>2,153,308</b>
Cash and deposits	188,930	225,778	407,446	475,341	331,063	408,491
Receivables	203,346	271,075	272,650	320,468	372,937	418,351
Other receivables	32,294	53,294	40,797	67,840	85,520	100,496
Inventories	361,434	472,184	488,809	579,306	677,915	772,639
Contract assets	177,474	222,671	280,519	298,295	354,352	418,150
Others	25,350	3,585	34,350	32,394	31,695	35,182
<b>Long-term assets</b>	<b>173,584</b>	<b>199,612</b>	<b>270,849</b>	<b>263,403</b>	<b>708,460</b>	<b>517,965</b>
PPE	8,949	11,054	17,227	16,116	19,570	23,872
Land held and cost for property development	110,510	139,021	203,849	197,879	639,482	444,564
Investment properties	9,514	22,922	23,652	23,287	23,287	23,409
Intangible/Goodwill	24,506	25,576	25,576	25,576	25,576	25,576
Others	20,105	1,038	545	545	545	545
<b>Total assets</b>	<b>1,162,413</b>	<b>1,448,198</b>	<b>1,795,420</b>	<b>2,037,048</b>	<b>2,806,456</b>	<b>3,266,336</b>
<b>Current liabilities</b>	<b>336,677</b>	<b>401,693</b>	<b>472,656</b>	<b>564,183</b>	<b>677,387</b>	<b>813,117</b>
Trade payables	182,714	195,493	178,806	250,773	277,402	314,816
Other payables	81,698	142,450	200,219	177,666	225,737	266,024
Short-term borrowings	41,528	40,861	82,083	113,655	150,972	210,107
Contract liabilities	3,797	2,701	5,853	4,360	4,445	5,233
Lease liabilities	1,310	1,771	1,769	2,402	2,921	3,457
Current tax payable	25,630	18,417	3,926	15,326	15,911	13,481
<b>Long-term Liabilities</b>	<b>199,386</b>	<b>165,883</b>	<b>307,092</b>	<b>251,896</b>	<b>669,874</b>	<b>675,411</b>
Long-term borrowings	180,687	159,138	300,905	237,631	658,247	661,782
Payables	13,808	2,792	-	8,476	4,707	5,653
Lease liabilities	2,655	3,030	4,924	4,629	5,559	6,835
Deferred tax liabilities	2,236	923	1,263	1,160	1,360	1,141
<b>Total Liabilities</b>	<b>536,063</b>	<b>567,575</b>	<b>779,748</b>	<b>816,078</b>	<b>1,347,261</b>	<b>1,488,528</b>
<b>Total Equity</b>	<b>626,349</b>	<b>880,623</b>	<b>1,015,672</b>	<b>1,220,970</b>	<b>1,459,195</b>	<b>1,777,808</b>
Common stock/Share capital	220,520	314,551	333,171	333,171	333,171	333,171
Retained earnings	398,018	566,078	665,792	868,819	1,118,327	1,437,967
Non-controlling interests	7,811	-5	-8	18,980	7,696	6,670
Others	-	-	16,717	-	-	-
<b>Total liabilities &amp; Total Equity</b>	<b>1,162,413</b>	<b>1,448,198</b>	<b>1,795,420</b>	<b>2,037,048</b>	<b>2,806,456</b>	<b>3,266,336</b>
Interest-bearing debt	223,525	201,769	384,757	353,689	812,141	875,346
Net interest-bearing debt	34,595	-24,008	-22,689	-121,652	481,078	466,855
Net debt to equity (%)	5.5%	-2.7%	-2.2%	-10.0%	33.0%	26.3%
Cash and deposits (%)	27.1%	27.0%	46.9%	40.9%	24.8%	27.3%
Receivables (%)	29.1%	32.4%	31.4%	27.5%	27.9%	28.0%
Inventories (%)	51.8%	56.5%	56.3%	49.8%	50.7%	51.7%
Trade and other payables (%)	26.2%	23.4%	24.3%	24.6%	24.1%	24.3%
ATO (%)	74.6%	64.0%	53.5%	61.0%	55.2%	49.2%
ROE (%)	30.1%	26.7%	18.2%	21.5%	19.1%	17.6%
ROA (%)	15.2%	15.4%	10.6%	12.6%	10.6%	9.4%

Source: Company, compiled by PRSB

Cash flow (MYR,000)	2020	2021	2022	2023E	2024E	2025E
<b>Operating cash flow</b>	<b>218,203</b>	<b>56,834</b>	<b>116,040</b>	<b>188,790</b>	<b>-49,991</b>	<b>169,348</b>
Pretax profits	215,943	279,079	250,810	337,777	360,408	400,872
Depreciation & Amortisation	1,772	2,396	3,363	3,297	4,047	4,856
Decrease in Account Receivable	65,757	67,729	1,575	75,056	52,468	45,415
Change in Inventories	148,185	110,750	16,625	107,265	98,609	94,724
Change in Account Payables	75,363	12,779	-16,687	71,962	26,628	37,414
Changes in Contract assets	63,682	45,197	57,848	20,495	56,057	63,798
Changes in Contract liabilities	-640	-1,096	3,152	1,307	85	789
Interest Expense	488	1,401	21,272	20,771	32,993	47,793
Change in Working Capital (WC)	-202,901	-211,992	-89,584	-129,547	-180,421	-165,733
Taxes	64,256	77,613	73,074	97,618	104,158	115,852
Other	267,156	63,563	3,253	54,110	-162,860	-2,589
<b>Investment cash flow</b>	<b>-104,947</b>	<b>-62,099</b>	<b>-38,031</b>	<b>-54,016</b>	<b>-476,885</b>	<b>-82,322</b>
Capex	-1,022	-44,477	-45,825	-37,741	-457,943	-63,602
Investments	-129,439	-18,042	7,655	-16,275	-18,942	-18,720
Proceed from disposal of PPE	10,773	420	139	-	-	-
Repayment from Director's related companies	14,741	-	-	-	-	-
<b>Financial cash flow</b>	<b>11,059</b>	<b>42,112</b>	<b>103,659</b>	<b>-69,080</b>	<b>382,598</b>	<b>-9,598</b>
Change in borrowings	8,124	-24,184	182,990	-28,023	457,933	62,670
Change in equity	39,256	97,570	135,049	18,972	-11,284	-1,026
Dividends paid	-15,857	-52,717	-63,867	-60,029	-64,051	-71,242
Other	-20,464	21,444	-150,513	-	-	-
<b>Change in cash &amp; equivalents</b>	<b>124,316</b>	<b>36,847</b>	<b>181,668</b>	<b>65,694</b>	<b>-144,278</b>	<b>77,427</b>
Cash & equivalent at FY-start	64,615	188,930	225,778	409,647	475,341	331,063
Cash & equivalent at FY-end	188,930	225,778	407,446	475,341	331,063	408,491
Free Cash Flow	113,257	-5,265	78,009	134,774	-526,876	87,026

Source: Company, compiled by PRSB

## ISSUER SPECIFIC REGULATORY DISCLOSURES

### Materially mentioned issuers

Issuer	Ticker	Price	Price date	Stock rating	Sector rating	Disclosures
--------	--------	-------	------------	--------------	---------------	-------------

**Due to time critical of this report, this information is unavailable at the time of publication.**

### DISCLAIMERS

Legal and Regulatory Notices (Electronic Communications)  
© 2018 PRSB.

#### Important disclosures

This research report is strictly confidential and has been prepared for information purposes only by Phillip Research Sdn Bhd (“PRSB”), a subsidiary of Phillip Capital Holdings Sdn Bhd (“PCH”) and is meant for circulation to its clients and clients of other subsidiaries companies of PCH particularly Phillip Mutual Berhad (“PMB”), Phillip Capital Management Sdn Bhd (“PCM”), Phillip Wealth Planners Sdn Bhd (“PWP”) and Phillip Capital Sdn Bhd (“PCSB”) (collectively refer to as Phillip Group other licensed intermediaries (“PGOLI”)) only or such other persons as may be deemed eligible to receive such research report, information or opinion contained herein. Neither the publication/communication nor any portion hereof may be reprinted, distributed, sold, resold, redistributed, copied, reproduced, published, republished, displayed, posted or transmitted in any form or media or by any means without the written consent of PRSB.

The policy of PRSB is to only publish research that is impartial, independent, clear, fair, and not misleading. Analysts never receive compensation from companies they cover. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to a research report as below. This research disclosure is for your information only and does not constitute any recommendation, representation or warranty. Absence of a disclosable position should not be taken as endorsement on the validity or quality of the research report or recommendation.

To maintain the independence and integrity of PRSB’s research, PGOLI activities such as fund management, dealing in securities (restricted to unit trust and private retirement scheme), dealing in derivatives, clearing for derivatives, financial planning and research business lines are distinct from one another. This means that PRSB is not part of and does not report to any of PGOLI. Accordingly, PGOLI does not supervise nor control the activities of PRSB’s research analysts. PRSB’s research analysts report to the Head of Research, who in turn report to PRSB’s senior management.

PRSB and PGOLI have in place internal controls designed to manage conflicts of interest that may arise as a result of PGOLI engaging in fund management, dealing in securities (restricted to unit trust and private retirement scheme), dealing in derivatives, clearing for derivatives, financial planning and PRSB activities. Some examples of these controls include: the use of information barriers and other information controls designed to ensure that confidential information is only shared on a “need to know” basis and in compliance with PRSB and PGOLI’s Chinese Wall policies and procedures; measures designed to ensure that interactions that may occur among PRSB’s research personnel, fund management, dealing in securities (restricted to unit trust and private retirement scheme), dealing in derivatives, clearing for derivatives, and financial planning, PGOLI’s financial product issuers and PRSB’s research analysts do not compromise the integrity and independence of PRSB’s research.

Neither analysts nor their household members/associates/may have a financial interest in, or be an officer, director or advisory board member of companies covered by the analyst unless disclosed herein. In circumstances where an analyst has a pre-existing holding in any securities under coverage, those holdings are grandfathered and the analyst is prohibited from trading such securities up to the date of the publication of this research report.

Unless specified otherwise, PRSB did not receive investment banking/non-investment banking income from, and did not manage/co-manage a public offering for, the listed company during the past 12 months, and it does not expect to receive investment banking compensation from the listed company within the coming three months. Unless mentioned otherwise, PRSB does not own a material disclosable position, and does not make a market, in the securities.

We hereby certify that the views expressed in this research report accurately reflect our views about the securities and/or the issuers and that no part of our compensation were or will be directly or indirectly related to the specific recommendation or views contained in this report or to any investment banking relationship with the subject company covered in this report (for the past one year) or otherwise any other relationship with such company which leads to receipt of fees from the company except in ordinary course of business of the company. We hereby confirm that our analyst(s) has/have not been placed under any undue

influence, intervention or pressure by any person(s) in compiling this research report. This report is prepared without any intention to raise, lower or maintaining the price of the securities covered or to induce the recipient to buy or sell the securities covered. In addition, our analyst(s) included herein attest that he/she/they was/were not in possession of any material, non-public price sensitive information regarding the subject company at the time of publication of the report. Save from the disclosure below (if any), we are not aware of any material conflict of interest.

Key to PRSB investment ratings:

Equity:

BUY: Total stock return (including dividends) expected to exceed 20% annually;

O-PF: Total expected return below 20% annually but exceeding market return;

U-PF: Total expected return positive but below market return;

SELL: Total return expected to be negative.

For relative performance, we benchmark the 12-month total forecast return (including dividends) for the stock against the 12-month forecast return (including dividends) for the market on which the stock trades.

ETFs (Criteria applies to rating assignments from 16th December 2019):

STRONG BUY: Total return (including dividends) expected to exceed 20% annually;

BUY: Total expected return below 20% but exceed 5% or then 1-year rate, whichever is higher;

SELL: Total return of not more than 5% or then 1-year rate, whichever is higher.

The ratings are based on the forecast total return (including dividends) over the next 12 months.

Funds:

The rating a mathematical scoring system that include risks (standard deviation, Sharpe Ratio) and returns (1-year, 3-year, 5-year and consistency) BUY: Total return (including income distribution) is positive and above peers' average while risk factors are low;

O-PF: Total return is positive and above peers' average but has higher risk factors;

SELL: Total return is negative.

For a history of the recommendations and price targets for companies mentioned in this report, as well as company specific disclosures, please write to: Phillip Research Sdn Bhd, B-18-6, Block B Level 18, Megan Avenue II, 12 Jalan Yap Kwan Seng, 50450 Kuala Lumpur, Malaysia.

The information, opinions and estimates herein are not directed at, or intended for distribution to or use by, any person or entity in any jurisdiction where doing so would be contrary to law or regulation or which would subject PRSB and/or its associate companies to any additional registration or licensing requirement within such jurisdiction. The information and statistical data herein have been obtained from sources we believe to be reliable. Such information has not been independently verified and we make no representation or warranty as to its accuracy, completeness or correctness. Any opinions or estimates herein reflect the judgment of PRSB at the date of this publication/communication and are subject to change at any time without notice. Where any part of the information, opinions or estimates contained herein reflects the views and opinions of a sales person (include but not limited to Financial Planners and Marketing Representative or a non-analyst), such views and opinions may not correspond to the published view of PRSB. This is not a solicitation or any offer to buy or sell. This publication/communication is for information purposes only and does not constitute any recommendation, representation, warranty or guarantee of performance. Any price target given in the report may be projected from one or more valuation models and hence any price target may be subject to the inherent risk of the selected model as well as other external risk factors. This is not intended to provide professional, investment or any other type of advice or recommendation and does not take into account the particular investment objectives, financial situation or needs of individual recipients. Before acting on any information in this publication/communication, you should consider whether it is suitable for your particular circumstances and, if appropriate, seek professional advice, including tax advice. PRSB, and PGOLI do not accept any responsibility and cannot be held liable for any person's use of, or reliance on the information and opinions contained herein. To the extent permitted by applicable securities laws and regulations, PRSB accepts no liability whatsoever for any direct or consequential loss arising from the use of this publication/communication or its contents. Where the publication does not contain ratings, the material should not be construed as research but is offered as factual commentary. It is not intended to, nor should it be used to form an investment opinion about the non-rated companies.

Subject to any applicable laws and regulations at any given time, PRSB, PGOLI and their respective affiliates or companies or individuals connected with PRSB may have used the information contained herein before publication and may have positions in, may from time to time purchase or sell or have a material interest in any of the securities mentioned or related securities, or may currently or in future have or have had a business or financial relationship with, or may provide or have provided investment banking, capital markets and/or other services to, the entities referred to herein, their advisors and/or any other connected parties. As a result, investors should be aware that PRSB, PGOLI and/or their respective affiliates or companies or such individuals may have one or more conflicts of interest. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to research reports. Details of the disclosable interest can be found in certain reports as required by the relevant rules and regulation. Disclosures therein include the position of PRSB and PGOLI only. Unless specified otherwise, PRSB did not receive any compensation or other benefits from the subject company covered in this publication/communication.

The analysts/contributors to this publication/communication may be employed by any relevant PGOLI entity, which is different from the entity that distributes the publication/communication in the respective jurisdictions.



PRSB, PGOLI and/or its officers, directors and employees, may, to the extent permitted by applicable law and/or regulation, deal as principal, agent, or otherwise, or have long or short positions in, or buy or sell, the securities, commodities or instruments, or options or other derivative instruments based thereon, of issuers or securities mentioned herein. PGOLI may also act as market maker or liquidity provider (within the meaning of applicable regulations in the UK) in the financial instruments of the issuer. Where the activity of market maker is carried out in accordance with the definition given to it by specific laws and regulations of the US or other jurisdictions, this will be separately disclosed within the specific issuer disclosures.

Investors should not consider this report as only a single factor in making their investment decision and, as such, the report should not be viewed as identifying or suggesting all risks, direct or indirect, that may be associated with any investment decision. PRSB produces a number of different types of research product including, among others, fundamental analysis and quantitative analysis; recommendations contained in one type of research product may differ from recommendations contained in other types of research product, whether as a result of differing time horizons, methodologies or otherwise. PRSB and PGOLI publishes research product in a number of different ways including the posting of product on the PGOLI portals and/or distribution directly to clients. Different groups of clients may receive different products and services from the research department depending on their individual requirements.

Figures presented herein may refer to past performance or simulations based on past performance which are not reliable indicators of future performance. Where the information contains an indication of future performance, such forecasts may not be a reliable indicator of future performance. Moreover, simulations are based on models and simplifying assumptions which may oversimplify and not reflect the future distribution of returns. Any figure, strategy or index created and published for illustrative purposes within this report is not intended for “use” as a “benchmark”.

Certain securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of, or income derived from, the investment.

With respect to Fixed Income Research: Recommendations fall into two categories: tactical, which typically last up to three months; or strategic, which typically last from 6-12 months. However, trade recommendations may be reviewed at any time as circumstances change. ‘Stop loss’ levels for trades are also provided; which, if hit, closes the trade recommendation automatically. Prices and yields shown in recommendations are taken at the time of submission for publication and are based on either indicative Bloomberg, Reuters or PGOLI prices or yields at that time. The prices and yields shown are not necessarily those at which the trade recommendation can be implemented.

The securities described herein may not have been registered under the US Securities Act of 1933 (the ‘1933 Act’), and, in such case, may not be offered or sold in the US or to US persons unless they have been registered under the 1933 Act, or except in compliance with an exemption from the registration requirements of the 1933 Act. Unless governing law permits otherwise, any transaction should be executed via PhillipCapital Group entity in your home jurisdiction.